News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eutropics Pharmaceuticals to Present Data on Personalized Diagnostic for AML Patient Management at American Society of Clinical Oncology 2013



5/16/2013 8:45:49 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Eutropics Pharmaceuticals Inc. announced today that Eutropics and The University of Texas MD Anderson Cancer Center will present results from a clinical study employing Eutropics’ proprietary PraediCare Dx (BH3 profiling) assay to discriminate therapeutic response in acute myeloid leukemia (AML) patients to standard-of-care-based chemotherapy.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES